What do recent clinical studies say about Tezspire’s effectiveness in managing severe asthma?
Based on available data, Tezspire has shown potential to help reduce asthma exacerbations and improve control in patients with severe asthma when added to standard therapy.
Understanding Tezspire’s Role in Asthma Treatment
People living with severe asthma often struggle to manage symptoms despite using multiple treatments. Tezspire is a new option designed to work differently than traditional asthma medications. Here’s a brief look at what makes it noteworthy:
- Tezspire targets a specific immune pathway that contributes to inflammation in asthma.
- It is used alongside current maintenance therapies, not as a replacement.
- Its role in patient care is typically reserved for those with persistent, severe symptoms.
This helps explain why many patients and providers are exploring whether it could improve outcomes when other medications fall short.
How Tezspire Works and Who It’s For
How it works
Tezspire (tezepelumab) is a monoclonal antibody that may work by blocking thymic stromal lymphopoietin (TSLP), a protein believed to trigger multiple inflammatory pathways in asthma.
By inhibiting TSLP activity, Tezspire reduces airway inflammation, which may lead to fewer severe asthma flare-ups in appropriate patients.
Clinical applications
According to published information, Tezspire is intended for use in patients aged 12 and older with severe asthma that is not controlled by inhaled corticosteroids and other maintenance treatments.
It may be suitable for patients regardless of eosinophil levels, offering an option for a broader group than some other biologics. Clinical evidence shows that it may reduce the frequency of asthma exacerbations.
Safety and Effectiveness
Safety profile
As reported in the patient information document, common side effects of Tezspire include sore throat, joint pain, back pain, and rash. It may also raise the risk of hypersensitivity reactions or injection site irritation.
Patients should be monitored for any allergic responses, especially after initial doses.
FDA approval and indications
Tezspire is FDA-approved as an add-on maintenance treatment for severe asthma in patients aged 12 and older. It is not used to treat acute asthma symptoms or attacks.
Discuss with your healthcare provider to determine if Tezspire fits your asthma treatment plan.
Access and Availability
How to obtain safely
IsraelPharm offers access to Tezspire for eligible international patients seeking FDA-approved asthma therapies. Their licensed pharmacy team can assist with availability and pricing details.
Always consult your healthcare provider before starting any new asthma treatment.
Key Takeaways
- Tezspire is a biologic medication developed to manage severe asthma by blocking TSLP.
- It may help reduce asthma flare-ups in patients not controlled by standard therapies.
- FDA-approved for individuals aged 12+ with severe asthma.
- Common side effects include throat discomfort, joint pain, and rash.
- Patients should consult their provider for personalized treatment advice.
FAQs
Can I use Tezspire every day?
No, Tezspire is given as a once-monthly injection, administered by a healthcare professional. It’s not a daily medication.
How quickly does Tezspire start working?
While response time can vary, some patients may notice fewer asthma flare-ups within months of starting therapy. Full effects may take longer to evaluate.
Is Tezspire safe for long-term use?
Data from the stepwise asthma management guide suggests that Tezspire may be suitable for ongoing use in appropriate cases, but all long-term therapy should be monitored by a doctor.
Is Tezspire better than other asthma biologics?
Tezspire may offer advantages for certain patients, especially because it is not limited to those with high eosinophil counts. However, effectiveness varies by individual.
How much does Tezspire cost through IsraelPharm?
Pricing can vary based on location, prescription details, and quantity. IsraelPharm’s support team can provide a cost estimate upon request.


